Introduction

The host welcomes Kristin Urima, CEO at Poseida Therapeutics, as they discuss the company's transition from AAV delivery to nanoparticle delivery and their focus on a fully allogeneic approach in cell therapy. They also delve into Poseida's three clinical stage programs, their manufacturing facility, and the significance of maintaining a special culture at the company.